Literature DB >> 23013487

Introducing the medical bioinformatics in Journal of Translational Medicine.

Samir K Brahmachari.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 23013487      PMCID: PMC3533924          DOI: 10.1186/1479-5876-10-202

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


× No keyword cloud information.

Launched with the promise of improving insights into human health and disease, the Human Genome Project a decade after its completion has revealed a wealth of information. The advent of next generation sequencing technologies and other high throughput measurements of ‘omics’ data, along with clinical phenotype association studies, have created a data deluge. However, explosive growth in biomedical data generation has not yet translated to proportionate increases in clinical returns. The announcement of the X-prize in genomics for sequencing 100 centenarians within 30 days at less than $1,000 per genome, and with an error rate less than one in a million base pairs, is expected to herald a new era, where whole genome sequencing will become routine clinical practice for diagnosis and prognosis for personalized healthcare [1]. However, this would only be possible if we are able to capture, curate and analyze clinical data with ‘omics’ datasets using novel informatics tools to establish correlations with high level of confidence. This major transformation that hoped to bridge the gap between researchers and clinicians will primarily be driven by transformation of silos of biomedical research to an integrative field of intensive data driven discovery. The new paradigm of scientific discovery arising out of this data exploration is referred to as the “Fourth Paradigm” [2] and combines data capture, theory and computation. This paradigm rests on the power of information technology and advance computing facility to effectively mine semantically linked datasets to derive patterns and predictive models. ‘Medical Bioinformatics’ holds immense promise in this area by equipping researchers with tools and resources to efficiently capture, curate and analyze the ‘big data’, while allowing clinicians and care-givers access to evidence based insights which could be effectively used for patient-care. The initial efforts on data collection of genotype-to-phenotype correlation studies have largely been carried under the Genome Wide Association studies (GWAS). Although the studies have contributed immensely towards exploring the genetic basis of complex diseases, many of the insights obtained by these studies could not be optimally extrapolated to clinical settings due to poor predictability of traits exclusively based on genetic markers, baring a few exceptions. Large-scale integrative analyses of these datasets are primarily limited by non-standard phenotype descriptions and limitations with data sharing due to ethical constrains. The field of genotype-to-phenotype association study requires new and effective measures to integrate standardized genotype and phenotype information, so as to enable their easy access and robust analyses by the researchers. The GEN2PHEN, is one of such endeavors that aims to efficiently gather and organize the web-based genetic information that fundamentally impacts human health and disease prognosis [3]. The project has achieved significant success in facilitating holistic viewing of genotype-to-phenotype (G2P) correlations by systematically integrating genetic variation databases of the human and model organisms, and further linking it to other biomedical knowledge sources through genome browser functionality. While organizing existing datasets still remains a challenge, it is evident that the next generation of biosensors and electronic gadgets which can collect and transmit information on vital signs and clinical parameters coupled with ubiquitous connectivity are poised to be the next big revolution in personalized healthcare, generating voluminous data on individuals. Systematic organization, and mining of this large repository of clinical information, derived from sensors, diagnostic labs and harnessing it for cost-effective and personalized healthcare would be a major challenge in the immediate future and has raised the need for new data handling, integration and web-based community workspace tools. The emerging concept of ‘cloud computing’ has the potential to address these concerns. Cloud computing allows for collection and storage of clinical data in an advanced information technology enabled fashion. Information transmitted through biosensors could be received and stored in a transparent manner and in a standardized electronic format. The information could be archived with additional non-clinical parameters, thus forming the basis of a biomedical database. Such cloud computing will increase the access and the workflow of electronic data to enable accurate analysis towards the discovery of new predictive biomarkers for disease predisposition. The advancement in techniques for data capture and curation of different types of data will further encourage adoption of an integrated, ‘System Biology’ platform for studying and analyzing these datasets. This approach will enable designing of accurate predictive mathematical models to study biological systems- intracellular networks, cells, organs, and any biological entity—by measuring and integrating genetic, proteomic and metabolic data. With respect to drug discovery, application of this approach will involve utilizing clinical samples from diseased and healthy (normal) individuals to uncover system biology markers and pathways targets, which are indicators of disease and potential targets for therapeutic interventions. Such efficient identification of novel drug target leads thus, has the potential to reduce the current prohibitively large costs of drug discovery by eliminating trial and error methods. It is also worth mentioning that the big data science of medical bionformatics, which has attracted big attention of funding agencies [4] will engage the expertise of medical scientists, bioinformaticians, computer scientists, and database experts, along with mathematicians and engineering experts in modelling and simulation of biosystems, with an objective of developing novel low-cost therapeutic applications. The Open Source Drug Discovery (OSDD) initiative [5,6] for system level understanding of Mycobacterium tuberculosis has created a new paradigm for distributed co-creation through crowd sourcing [7] and the application of social media for data gathering. This is going to be the new frontier of application of bioinformatics in medical research. The Medical bioinfromatics section in Journal of Translational Medicine would aim to promote research in this area by providing a high-quality publishing media for path-breaking and innovative research in the area.
  5 in total

1.  Science in India. Crowd-sourcing drug discovery.

Authors:  Pallava Bagla
Journal:  Science       Date:  2012-02-24       Impact factor: 47.728

2.  India takes an open source approach to drug discovery.

Authors:  Seema Singh
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

3.  Contest to sequence centenarians kicks off.

Authors:  Monya Baker
Journal:  Nature       Date:  2012-07-23       Impact factor: 49.962

4.  Crowd sourcing a new paradigm for interactome driven drug target identification in Mycobacterium tuberculosis.

Authors:  Rohit Vashisht; Anupam Kumar Mondal; Akanksha Jain; Anup Shah; Priti Vishnoi; Priyanka Priyadarshini; Kausik Bhattacharyya; Harsha Rohira; Ashwini G Bhat; Anurag Passi; Keya Mukherjee; Kumari Sonal Choudhary; Vikas Kumar; Anshula Arora; Prabhakaran Munusamy; Ahalyaa Subramanian; Aparna Venkatachalam; S Gayathri; Sweety Raj; Vijaya Chitra; Kaveri Verma; Salman Zaheer; J Balaganesh; Malarvizhi Gurusamy; Mohammed Razeeth; Ilamathi Raja; Madhumohan Thandapani; Vishal Mevada; Raviraj Soni; Shruti Rana; Girish Muthagadhalli Ramanna; Swetha Raghavan; Sunil N Subramanya; Trupti Kholia; Rajesh Patel; Varsha Bhavnani; Lakavath Chiranjeevi; Soumi Sengupta; Pankaj Kumar Singh; Naresh Atray; Swati Gandhi; Tiruvayipati Suma Avasthi; Shefin Nisthar; Meenakshi Anurag; Pratibha Sharma; Yasha Hasija; Debasis Dash; Arun Sharma; Vinod Scaria; Zakir Thomas; Nagasuma Chandra; Samir K Brahmachari; Anshu Bhardwaj
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

5.  HGVbaseG2P: a central genetic association database.

Authors:  Gudmundur A Thorisson; Owen Lancaster; Robert C Free; Robert K Hastings; Pallavi Sarmah; Debasis Dash; Samir K Brahmachari; Anthony J Brookes
Journal:  Nucleic Acids Res       Date:  2008-10-23       Impact factor: 16.971

  5 in total
  5 in total

1.  Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations.

Authors:  Ping Huang; Shouyi Yu; Changyou Wu; Lijun Liang
Journal:  J Transl Med       Date:  2013-02-22       Impact factor: 5.531

2.  Analysis of candidate genes has proposed the role of y chromosome in human prostate cancer.

Authors:  Pegah Khosravi; Javad Zahiri; Vahid H Gazestani; Samira Mirkhalaf; Mohammad Akbarzadeh; Mehdi Sadeghi; Bahram Goliaei
Journal:  Iran J Cancer Prev       Date:  2014

3.  Comparative Analysis of Prostate Cancer Gene Regulatory Networks via Hub Type Variation.

Authors:  Pegah Khosravi; Vahid H Gazestani; Mohammad Akbarzadeh; Samira Mirkhalaf; Mehdi Sadeghi; Bahram Goliaei
Journal:  Avicenna J Med Biotechnol       Date:  2015 Jan-Mar

4.  Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression.

Authors:  Yin Li; Wanwipa Vongsangnak; Luonan Chen; Bairong Shen
Journal:  BMC Med Genomics       Date:  2014-05-08       Impact factor: 3.063

5.  Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets.

Authors:  Rohit Vashisht; Ashwini G Bhat; Shreeram Kushwaha; Anshu Bhardwaj; Samir K Brahmachari
Journal:  J Transl Med       Date:  2014-10-11       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.